Erinacine C

Erinacine C belongs to the cyathane diterpenoid family produced by cultured Hericium erinaceus mycelium and, like erinacine A, was identified through screening for low-molecular-weight NGF inducers. Historically it has been reported as one of the most active erinacines for stimulating NGF biosynthesis in cell-based assays, making it a key contributor to the neurotrophic reputation of mycelial extracts ^[2][3].

Its best-defined mechanism comes from work in lipopolysaccharide-stimulated BV2 microglial cells, where erinacine C reduced nitric oxide, interleukin-6, tumor necrosis factor-alpha and inducible nitric oxide synthase, while inhibiting NF-kappaB activation and IkappaB-alpha phosphorylation. In parallel it suppressed Keap1 and enhanced nuclear Nrf2 with induction of heme oxygenase-1 (HO-1), a canonical antioxidant and anti-inflammatory switch ^[1]. This dual action, dampening the NF-kappaB inflammatory arm while activating the Nrf2/HO-1 cytoprotective arm, is the same homeostatic logic highlighted in broader reviews of Hericium neuroprotection ^[3][4].

Because microglial overactivation and oxidative stress are shared drivers across neurodegenerative and neuroinflammatory conditions, erinacine C is discussed as a mechanistically attractive complement to the more famous erinacine A, contributing anti-inflammatory tone alongside neurotrophic induction. As with the other erinacines, evidence remains preclinical and standardization of content across products is a practical limitation ^[4].

Erinacine C is present in Hericium erinaceus mycelium consumed as a dietary supplement, and no specific safety signals have been reported for the isolated diterpenoid, though dedicated human toxicology is lacking. Anti-inflammatory and Nrf2-activating compounds are generally well tolerated, but purified erinacine C remains a research-grade material without established dosing, and its use in pregnancy, lactation or alongside immunomodulatory therapy is uncharacterized.

Erinacine C was characterized among the early erinacines isolated from Hericium erinaceus mycelium during the 1990s natural-product campaigns that mapped the NGF-inducing diterpenoids of Lion's Mane. Its anti-neuroinflammatory mechanism was detailed in later cell-based studies, notably a 2019 investigation in BV2 microglia that established its Nrf2/HO-1 and NF-kappaB actions.

Erinacine C is respected among researchers as a potent NGF inducer and a mechanistically clean anti-inflammatory diterpenoid, but it is far less commercialized than erinacine A and is rarely quantified on supplement labels. It is viewed mainly as a research lead that helps explain the anti-inflammatory dimension of Lion's Mane mycelium.